Clinical trials
Prediabetic State trials in Canada with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2011 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Unknown status | 6 |
| Recruiting | 5 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Manitoba | 4 |
| University of Toronto | 4 |
| Gelesis, Inc. | 2 |
| Laval University | 2 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 2 |
| SciMar Ltd. | 2 |
| University of Alberta | 2 |
| University of British Columbia | 2 |
| Université de Sherbrooke | 2 |
| Brescia University College | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prediabetic State | 32 |
| Insulin Resistance | 8 |
| Obesity | 8 |
| Diabetes Mellitus, Type 2 | 7 |
| Overweight | 6 |
| Diabetes Mellitus | 5 |
| Glucose Intolerance | 4 |
| Metabolic Syndrome | 3 |
| Cardiovascular Diseases | 2 |
| Hyperglycemia | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.